TECHX

Pharma

• Background: Pharma is a genuinely enormous, mature market (~$1.7-2.0 trillion in 2026), growing mid-single digits. MedTech is smaller (~$500-740 billion depending on scope), growing slightly faster (~5-9% CAGR).
• Gains: Biologics dominate pharma's growth mix (GLP-1s, ADCs); over $300 billion in manufacturing capacity investment flowed in 2024-2026; AI-in-medical-devices is a small but explosively fast-growing sub-segment (44%+ CAGR).
• Reasons to invest: demographic tailwinds (aging population, chronic disease) that don't reverse in downturns, non-discretionary demand, massive R&D reinvestment, established large-cap names with decades of track record (J&J, Medtronic, Stryker, AstraZeneca, Eli Lilly).
• Risks: this is the slowest-growing sector covered in your whole tech/health workbook (4-9% CAGR vs. double/triple-digit growth elsewhere), patent cliffs, heavy regulatory and reimbursement exposure, long/expensive/uncertain drug development cycles, and wide estimate dispersion especially on the MedTech side.

Here's a focused deep-dive on those three specific angles — biologics, AI-enabled devices, and biotech/genomics — since they're the fastest-growing, most technically distinct pockets sitting inside your broader pharma/medtech and biotech research.BiologicsWhat it is: Drugs made from living organisms (proteins, antibodies, cell therapies) rather than chemically synthesized small molecules — includes monoclonal antibodies, GLP-1 therapies, antibody-drug conjugates (ADCs), and gene/cell therapies.Why it's the growth engine inside pharma:

• Biologics are expected to hold roughly 76% of the global pharmaceutical market in 2026 — no longer a niche category, but the majority of pharma value.
• Biologics and biosimilars are expanding at a faster clip than pharma overall (~10.6% CAGR through 2031), outpacing the broader ~5-8% pharma CAGR, driven by blockbuster antibody patent cliffs opening room for biosimilar competition.
• GLP-1 therapies and ADCs are singled out as the key innovation drivers, particularly in cardiometabolic and oncology — the same GLP-1 category (Ozempic/Wegovy-style drugs) that's become one of the most commercially significant drug classes in years.
• Concrete capital commitment: Eli Lilly's $27 billion multi-site manufacturing build-out and AstraZeneca's $50 billion biologics push are real, dated capacity investments — not just R&D promises.

Key risk specific to biologics: They're manufactured, not synthesized, meaning production is far more complex and capital-intensive than small-molecule drugs — a single contamination or process failure can shut down a facility for months. Biosimilar competition also erodes originator revenue faster than small-molecule generics historically did, once patents lapse.AI-enabled medical devicesWhat it is: The AI software layer applied to medtech — diagnostic imaging, robotic-assisted surgery, predictive/monitoring devices, AI-powered diagnostics.Why it's notable:

• This is the fastest-growing sub-segment in the entire pharma/medtech/biotech space covered in our conversation: the global AI-in-medical-devices market is set to grow from $32.21 billion in 2025 to around $886.39 billion by 2034, a 44.53% CAGR.
• Real-world hospital adoption is already substantial, not speculative: 55% of hospitals now use AI diagnostics and 48% use robotic-assisted surgical platforms.
• It directly links your pharma/medtech interest to your existing AI research — this is one of the clearest, most concrete applications of AI investment themes into a defensive healthcare sector.

Key risk specific to AI devices: The eye-catching CAGR starts from a genuinely small base (~$32 billion) — a reminder (consistent with the AI-in-robotics pattern already flagged) that percentage growth can look dramatic on small categories. Regulatory approval pathways for AI-driven diagnostics are also still evolving — the FDA and equivalent bodies are still building frameworks for how to approve software that updates/learns over time, which is a different regulatory problem than approving a static device.Biotech/genomicsWhat it is: The R&D and platform layer underneath biologics — gene/cell therapy platforms, DNA/RNA sequencing, and bioinformatics (the data/software tools used to analyze genomic data).Why it connects directly to biologics and AI devices:

• Genomics is growing faster than pharma overall — most estimates put it in the high-teens CAGR range through the early 2030s, versus pharma's mid-single-digit pace.
• Pharmaceutical and biotech companies represent 54.80% of genomics end-use market share — genomics is now largely how new biologics get discovered and targeted, not a separate, disconnected field. This is the direct technical link between your biotech/genomics interest and the biologics growth story above.
• Bioinformatics (data/software layer) is growing even faster than genomics itself, at roughly 21% CAGR — and this is where AI and genomics converge most directly, since AI-powered analysis of genomic data is one of the more credible near-term AI applications in healthcare, tying back to the AI-devices theme too.
• Cell & gene therapy (the clinical output of genomics research) is projected at a 19.7% CAGR — faster than biotech overall, and directly overlapping with the biologics growth story since gene/cell therapies are a biologics sub-category.

Key risk specific to genomics: Talent shortage is the most acute constraint here — genomics needs people with both deep biology and computational/bioinformatics skills, and that "double domain" talent pool is genuinely scarce, creating real execution bottlenecks even for well-funded companies.How the three connectThese aren't three separate bets — they're increasingly one value chain: genomics research identifies drug targets → biologics (especially gene/cell therapies and ADCs) turn those targets into treatments → AI-enabled devices increasingly diagnose who needs them and monitor outcomes. A single company (or a workbook tab) touching all three — say, a gene-therapy biotech using AI-assisted target discovery — sits at the convergence point of your AI, biotech, and medtech research all at once.